| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
There are not many cancer patients receiving well-controlled pain management, and therefore the development of more effective analgesics are required now. In recent years, it revealed that transient receptor potential (TRP) channels expressing primary sensory neurons played an important role for cancer pain. Moreover, it was reported that QX-314, which was one of the derivatives of lidocaine, a local anesthetic, suppressed the activation of voltage-gated sodium channel (Nav) in neurons expressing both TRP and Nav. However, the detailed pharmacological and/or analgesic actions of lidocaine derivatives are not well known.
In this study, therefore, we focused on the derivatives of lidocaine for development of novel analgesics, which specifically block TRP-expressing nerves, and evaluated the pharmacologic actions of these lidocaine derivatives on cancer pain.
|
